The 15 medicines included in the initiative include three branded medicines: valsartan ... from Novartis' Sandoz unit that are used to treat heart failure and hypertension (amlodipine, bisoprolol ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in ...

Objective: The aim of this study was to compare the antihypertensive efficacy and tolerability of the calcium channel antagonist amlodipine besylate versus the angiotensin II type 1 receptor ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Background: This study set out to assess the safety and efficacy of amlodipine in two cohorts of patients who were attended in primary- and specialised-care centres, respectively. Methods ...

We evaluated the novel use of valsartan to attenuate the occurrence of and progression of pulmonary vein stenosis following total anomalous pulmonary venous connection surgery. Subclinical pulmonary ...

Sorry, no items found. Please try again with different keywords.